Terminated NA INTERVENTIONAL NCT00272766

Macugen for Histoplasmosis

Macugen for Histoplasmosis-An Open-Label, Single-Site, Comparative, Prospective Case Series

Sponsor: Barnes Retina Institute

Conditions Choroidal Neovascularization Ocular Histoplasmosis

Updated 6 times since 2017 Last updated: Oct 25, 2006 Started: Feb 28, 2006 Completion: May 31, 2007

This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

Terminated

This trial was terminated. No reason was provided.

Other Choroidal Neovascularization trials with similar outcome

Browse all Choroidal Neovascularization trials

This NA trial investigates Choroidal Neovascularization and Ocular Histoplasmosis and is currently terminated or withdrawn. Barnes Retina Institute leads this study, which shows 6 recorded versions since 2006 — indicating limited longitudinal coverage. The change history captured here reflects the iterative nature of clinical trial conduct.

Status Flow

Change History

6 versions recorded

Sep 2025 — Present [monthly]

Terminated NA
Sep 2024 — Sep 2025 [monthly]

Terminated NA
Jul 2024 — Sep 2024 [monthly]

Terminated NA
Jan 2021 — Jul 2024 [monthly]

Terminated NA
Jun 2018 — Jan 2021 [monthly]

Terminated NA

▶ Show 1 earlier version

Jan 2017 — Jun 2018 [monthly]

Terminated NA

First recorded

Feb 2006

Trial started

Per CT.gov start date — pre-dates our first snapshot

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:

Barnes Retina Institute
Pfizer

Data source: Barnes Retina Institute

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

• St Louis, United States